Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo de revisión (ReviewArticle)

Tribbles pseudokinases: Fine tuning of cell signaling with implications in metabolism, inflammation and cancer

  • Velasco Díez, Guillermo
  • Lorente Pérez, María Del Mar
Within the family of protein kinases there is a subgroup of ‘evolutionarily related members of the total human kinome’ that are devoid (or have very limited) enzymatic activity. These proteins, so-called pseudokinases, play important functions thanks to their capacity to establish regulatory protein–protein interactions. Specifically, this opinion article focuses on a group of pseudokinases called Tribbles. Tribbles (Trbl) was originally discovered in Drosophila, followed by the subsequent identification of their orthologs in mammals (TRIB1, TRIB2, TRIB3, and STK40). Work over the last decades has shown how these proteins contribute to fine-tuning key signaling pathways involved in the regulation of proliferation, differentiation, inflammation and adaptation to nutritional changes. Accordingly, dysregulation of Tribbles proteins (TRIBs) contributes to the establishment and progression of insulin resistance, obesity, type II diabetes, atherosclerosis and cancer. Here, we will discuss some of the mechanisms by which Tribbles pseudokinases carry out their functions and the crucial importance of cell context in defining the precise role played by each of the TRIBs, with emphasis on TRIB1 and TRIB3, under different physiopathological situations.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza Pérez, Janire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo Pérez, Arkaitz
  • Liz Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface-enhanced Raman scattering (SERS) can be used for the label-free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self-assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel-based three-dimensional cancer model, which recreates the tumor microenvironment, for the real-time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.-M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM-2017-0720). C.G.-A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI-2016-28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI-HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106-16, also participated by A. Gomez-Munoz), the BBVA foundation, the MINECO (SAF2016-79381-R (FEDER/EU); Severo Ochoa Excellence Program SEV-2016-0644-18-1; Excellence Networks SAF2016-81975-REDT), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17-00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co-funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV-2015-0496
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James D.
  • Gutiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar López, Haizea
  • Izeta Permisán, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Del Sol, Antonio
  • Martínez Chantar, María Luz
  • Barrio Olano, María Rosa
  • Serra, Eduard
  • Lazaro, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay Bañares, Ana María
  • Carracedo Pérez, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment., This work was funded by grants to AW from the Spanish Association Against Cancer (AECC; JP Vizcaya); Spanish Ministry of Science, Innovation and Universities (MCIU)/Agencia Estatal de Investigacion (AEI)/European Regional Development Fund (FEDER), European Union (EU) (Subprograma Ramon y Cajal RYC2010-06901; Proyectos Retos Investigacion RTI2018-097503-B-I00, SAF2015-65360-R; Proyectos Explora Ciencia SAF2015-72416-EXP; Proyectos Europa Excelencia SAF2015-62588-ERC); the BBVA Foundation; Basque Department of Industry, Tourism and Trade (Elkartek) and Education (PI2013-46); Fundacion Vasca de Innovacion e Investigacion Sanitarias EiTB Maratoia (BIO13/CI/015); the Neurofibromatosis Therapeutic Acceleration Program; and the European Research Council (consolidator grant under the EU's Horizon 2020 research and innovation programme; grant agreement 865157). MVR is grateful for the support of a 2017 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation), Accion Estrategica Ciber Emergentes 2018 (Ciberehd-ISCIII), and Gilead Sciences International Research Scholars Program in Liver Disease. The work of AC is supported by the Basque Department of Industry, Tourism and Trade (Elkartek) and Education (IKERTALDE IT1106-16); the BBVA Foundation; the MCIU/AEI (SAF2016-79381-R [FEDER/EU]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks SAF20168-1975-REDT); the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (IDEAS175CARR, GCTRA18006CARR); La Caixa Foundation (HR17-00094); and the European Research Council (Starting Grant 336343, PoC 754627). MG was supported by the Intramural Research Program of the National Institute on Aging, NIH. MPI is grateful for the support of the Basque Government of Education fellowship. MTC is grateful for the support of "Ayudas para contratos predoctorales para la formacion de doctores" (MCIU/AEI/FEDER, EU). COH acknowledges funding from Brain Tumour Research. RB acknowledges MCIU/AEI/FEDER, EU (BFU2014-52282-P and BFU2017-84653-P). ES and CL are supported by the Carlos III National Health Institute funded by FEDER funds - a way to build Europe (CIBERONC) and the Government of Catalonia (2017SGR496). MLM-C acknowledges support from MCIU/AEI/FEDER, EU (SAF2017-87301-R); Asociacion Espanola Contra El Cancer (AECC); AECC Canceres Raros; BBVA Biomedicina (UMBRELLA); and La CAIXA Foundation (LCF/PR/HP17/52190004). AP was supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG 2018 Id.21548). CIBERehd is funded by the Instituto de Salud Carlos III. We thank MCIU for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

  • Araujo, Angela M.
  • Abaurrea Larrañaga, Andrea
  • Azcoaga Azcoaga, Peio
  • López Velazco, Joanna Inés
  • Manzano, Sara
  • Rodríguez Martínez, Javier
  • Rezola, Ricardo
  • Egia Mendikute, Leire
  • Valdés Mora, Fátima
  • Flores, Juana M.
  • Jenkins, Liam
  • Pulido, Laura
  • Osorio Querejeta, Iñaki
  • Fernández Nogueira, Patricia
  • Ferrari, Nicola
  • Viera, Cristina
  • Martín Martín, Natalia
  • Tzankov, Alexandar
  • Eppenberger Castori, Serenella
  • Álvarez López, Isabel
  • Urruticoechea, Ander
  • Bragado, Paloma
  • Coleman, Nicholas
  • Palazón García, Francisco de Asís
  • Carracedo Pérez, Arkaitz
  • Gallego Ortega, David
  • Calvo González, Fernando
  • Isacke, Clare M.
  • Muñoz Caffarel, Maria
  • Lawrie, Charles
[EN] The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression., This work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Metastatic hormone-naïve prostate cancer: a distinct biological entity

  • Corres Mendizabal, Jon
  • Zacchi, Francesca
  • Martín Martín, Natalia
  • Mateo, Joaquín
  • Carracedo Pérez, Arkaitz
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions., We are thankful to Kathrin Keim for support with English editing. The work of A.C. is supported by the Basque Department of Industry, Tourism, and Trade (Elkartek), the BBVA Foundation (Becas Leonardo), the Ministerio de Ciencia e Innovación (MICINN; PID2022-141553OB-I0 ERDF (European Regional Development Fund)/EU]; the Fundación CRIS Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the Spanish Association Against Cancer (AECC; GCTRA18006CARR), the Fundación Jesús Serra, the iDIFFER Network of Excellence (RED2022-134792-T), the AstraZeneca Award for young scientists (2023 call) and the European Research Council (consolidator grant 819242). CIBERONC was cofunded with FEDER funds and funded by the Instituto de Salud Carlos III (ISCIII). J.M. is supported by a CRIS Talent Award (TALENT20-10) and a Department of Defense Congressionally Directed Medical Research Program (CDMPR) Physician-Science Award (PC220307). VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Foundation for Oncological Studies and Research (FERO) and the Centres de Recerca de Catalunya (CERCA) Programme from Generalitat de Catalunya for their support.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Metabolic adaptations in prostate cancer

  • Pujana Vaquerizo, Mikel
  • Bozal Basterra, Laura
  • Carracedo Pérez, Arkaitz
Prostate cancer is one of the most commonly diagnosed cancers in men and is a major cause of cancer-related deaths worldwide. Among the molecular processes that contribute to this disease, the weight of metabolism has been placed under the limelight in recent years. Tumours exhibit metabolic adaptations to comply with their biosynthetic needs. However, metabolites also play an important role in supporting cell survival in challenging environments or remodelling the tumour microenvironment, thus being recognized as a hallmark in cancer. Prostate cancer is uniquely driven by androgen receptor signalling, and this knowledge has also influenced the paths of cancer metabolism research. This review provides a comprehensive perspective on the metabolic adaptations that support prostate cancer progression beyond androgen signalling, with a particular focus on tumour cell intrinsic and extrinsic pathways., We are grateful to the Carracedo lab for valuable input, and to Kathrin Keim for the help with English editing. A. Carracedo is funded by the Basque Department of Industry, Tourism and Trade (Elkartek), the BBVA foundation (Becas Leonardo), the MICINN (PID2022-141553OB-I0 (FEDER/EU); La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation CEX2021-001136-S), 2023 AstraZeneca Award for Young scientists in oncology, European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), Vencer el Cáncer Foundation, iDIFFER network of Excellence (RED2022-134792-T), Asociación Española Contra el Cáncer (GCTRA18006CARR) and the European Research Council (Consolidator Grant 819242). L. Bozal was supported by the AECC Foundation (POSTD19048BOZA). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Integrative analysis of transcriptomics and clinical data uncovers the tumor- suppressive activity of MITF in prostate cancer

  • Valcarcel Jimenez, Lorea
  • Macchia, Alice
  • Martín Martín, Natalia
  • Cortazar, Ana Rosa
  • Schaub Clerigué, Ariane
  • Pujana Vaquerizo, Mikel
  • Fernández Ruiz, Sonia
  • Lacasa-Viscasillas, Isabel
  • Santos Martin, Aida
  • Loizaga Iriarte, Ana
  • Unda Urzaiz, Miguel
  • Hermanova, Ivana
  • Astobiza, Ianire
  • Graupera i Garcia-Milà, Mariona
  • Starkova, Julia
  • Sutherland, James David
  • Barrio, Rosa
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Torrano, Verónica
The dysregulation of gene expression is an enabling hallmark of cancer. Computational analysis of transcriptomics data from human cancer specimens, complemented with exhaustive clinical annotation, provides an opportunity to identify core regulators of the tumorigenic process. Here we exploit well-annotated clinical datasets of prostate cancer for the discovery of transcriptional regulators relevant to prostate cancer. Following this rationale, we identify Microphthalmia-associated transcription factor (MITF) as a prostate tumor suppressor among a subset of transcription factors. Importantly, we further interrogate transcriptomics and clinical data to refine MITF perturbation-based empirical assays and unveil Crystallin Alpha B (CRYAB) as an unprecedented direct target of the transcription factor that is, at least in part, responsible for its tumor-suppressive activity in prostate cancer. This evidence was supported by the enhanced prognostic potential of a signature based on the concomitant alteration of MITF and CRYAB in prostate cancer patients. In sum, our study provides proof-of-concept evidence of the potential of the bioinformatics screen of publicly available cancer patient databases as discovery platforms, and demonstrates that the MITF-CRYAB axis controls prostate cancer biology.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza, Ianire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface‐enhanced Raman scattering (SERS) can be used for the label‐free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self‐assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel‐based three‐dimensional cancer model, which recreates the tumor microenvironment, for the real‐time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496.J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cancertool: A visualization and representation interface to exploit cancer datasets

  • Cortázar, Ana R.
  • Torrano, Verónica
  • Martín-Martín, Natalia
  • Caro-Maldonado, Alfredo
  • Camacho, Laura
  • Hermanova, Ivana
  • Guruceaga, Elizabeth
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Gomis, Roger R.
  • Apaolaza, Iñigo
  • Quesada, Víctor
  • Trka, Jan
  • Gómez-Muñoz, Antonio
  • Vincent, Silvestre
  • Bustelo, Xosé R.
  • Planes, Francisco J.
  • Aransay, Ana M.
  • Carracedo, Arkaitz
With the advent of OMICs technologies, both individual research groups and consortia have spear-headed the characterization of human samples of multiple pathophysiologic origins, resulting in thousands of archived genomes and transcriptomes. Although a variety of web tools are now available to extract information from OMICs data, their utility has been limited by the capacity of nonbioinformatician researchers to exploit the information. To address this problem, we have developed CANCERTOOL, a web-based interface that aims to overcome the major limitations of public transcriptomics dataset analysis for highly prevalent types of cancer (breast, prostate, lung, and colorectal). CANCERTOOL provides rapid and comprehensive visualization of gene expression data for the gene(s) of interest in well-annotated cancer datasets. This visualization is accompanied by generation of reports customized to the interest of the researcher (e.g., editable figures, detailed statistical analyses, and access to raw data for reanalysis). It also carries out gene-to-gene correlations in multiple datasets at the same time or using preset patient groups. Finally, this new tool solves the time-consuming task of performing functional enrichment analysis with gene sets of interest using up to 11 different databases at the same time. Collectively, CANCERTOOL represents a simple and freely accessible interface to interrogate well-annotated datasets and obtain publishable representations that can contribute to refinement and guidance of cancer-related investigations at all levels of hypotheses and design., We are grateful to Iñaki Lazaro for the design of the tumor type logos, Evarist Planet and Antoni Berenguer for insightful discussions, and the Carracedo lab for valuable input. V. Torrano is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia and the Basque Department of Health (2016111109). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the Department of Education (IKERTALDE IT1106-16, also participated by A. Gomez-Muñoz), the BBVA Foundation, the MINECO [SAF2016-79381-R (FEDER/EU)]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks (SAF2016-81975-REDT), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC IDEAS16 (IDEAS175CARR), and the European Research Council (Starting Grant 336343, PoC 754627). CIBERONC was cofunded with FEDER funds. The work of A. Aransay is supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia County, CIBERehd Network, and Spanish MINECO the Severo Ochoa Excellence Accreditation (SEV-2016-0644). I. Apaolaza is funded by a Basque Government predoctoral grant (PRE_2017_2_0028). X.R. Bustelo is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO; SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Society against Cancer (GC16173472GARC). Funding from MINECO to X.R. Bustelo is partially contributed by the European Regional Development Fund. The work of F.J. Planes is supported by the MINECO (BIO2016-77998-R) and ELKARTEK Programme of the Basque Government (KK-2016/00026).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer

  • Orea-Soufi, Alba
  • Castillo, Sonia
  • Salvador-Tormo, Nélida
  • Martín-Cabrera, Paola
  • Recuero, Silvia
  • Gabicagogeascoa, Estíbaliz
  • Moreno-Valladares, Manuel
  • Mendiburu-Eliçabe, Marina
  • Blanco-Gómez, Adrián
  • Ramos-Pittol, José Miguel
  • García-Taboada, Elena
  • Ocaña, Alberto
  • Cimas, Francisco J.
  • Matheu, Ander
  • Álvarez-López, Isabel
  • Velasco, Guillermo
  • Lorente, Mar
© 2021 by the authors., [Background]: Tribbles pseudokinase 3 (TRIB3) has been proposed to both promote and restrict cancer generation and progression. However, the precise mechanisms that determine this dual role of TRIB3 in cancer remain to be understood. In this study we aimed to investigate the role of TRIB3 in luminal breast cancer, the most frequent subtype of this malignancy. [Methods]: We genetically manipulated TRIB3 expression in a panel of luminal breast cancer cell lines and analyzed its impact on cell proliferation, and the phosphorylation, levels, or subcellular localization of TRIB3 and other protein regulators of key signaling pathways in luminal breast cancer. We also analyzed TRIB3 protein expression in samples from luminal breast cancer patients and performed bioinfor-matic analyses in public datasets. Results: TRIB3 enhanced the proliferation and AKT phosphoryla-tion in luminal A (HER2-) but decreased them in luminal B (HER2+) breast cancer cell lines. TRIB3 negatively regulated the stability of HER2 in luminal B breast cancer cell lines. TRIB3 expression was associated with increased disease-free survival and a better response to therapy in luminal breast cancer patients. [Conclusions]: Our findings support the exploration of TRIB3 as a potential biomarker and therapeutic target in luminal breast cancer., This work was funded by the Instituto de Salud Carlos III (ISCIII) and confounded by the European Regional Development Fund (ERDF), “A way to make Europe”, grant number PI18/00442 integrated into the State Plan for R & D + I 2017-2020; by the European Commission through the Horizon 2020 European Training Networks program, grant number H2020-MSCA-ITN308 2016 721532; and by the Breast Cancer Now (formerly Breast Cancer Campaign) foundation, grant number 2012NovSP033. Alba Orea-Soufi was supported by a predoctoral FPU contract from Spanish Government. Work in SC-L group is supported by a MINECO/FEDER research grant RTI2018-094130-B-100.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

  • Araujo, Angela M.
  • Abaurrea, Andrea
  • Azcoaga, Peio
  • López-Velazco, Joanna I.
  • Manzano, Sara
  • Rodríguez, Javier
  • Rezola, Ricardo
  • Egia-Mendikute, Leire
  • Valdés-Mora, Fátima
  • Flores, Juana M.
  • Jenkins, Liam
  • Pulido, Laura
  • Osorio-Querejeta, Iñaki
  • Fernández-Nogueira, Patricia
  • Ferrari, Nicola
  • Viera, Cristina
  • Martín-Martín, Natalia
  • Tzankov, Alexandar
  • Eppenberger-Castori, Serenella
  • Álvarez-López, Isabel
  • Urruticoechea, Ander
  • Bragado, Paloma
  • Coleman, Nicholas
  • Palazón, Asís
  • Carracedo, Arkaitz
  • Gallego-Ortega, David
  • Calvo, Fernando
  • Isacke, Clare M.
  • Caffarel, María M.
  • Lawrie, Charles H.
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression., This work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pseudokinases, Tribbles Proteins and Cancer

  • Velasco, Guillermo
  • Link, Wolfgang
The human kinome comprises 518 protein kinases, of which approximately 10% lack one or more of the conserved amino acids necessary for catalytic activity. These proteins are categorized as pseudokinases and are predicted to be inactive enzymatically [1]. Pseudokinases are believed to primarily signal via noncatalytic mechanisms, such as protein–protein interactions, contributing to the development of various human diseases. Recently, this class of kinase-like proteins has emerged as a promising target for drug development [2]. Several pseudokinases have been implicated in regulating signaling pathways involving receptor tyrosine kinases, LKB1/AMPK, AKT, MAPKs, and other pathways associated with cancer initiation and progression. Among them, the Tribbles family of pseudokinases, including TRIB1, TRIB2, and TRIB3, has garnered significant attention in the past decade due to their ability to modulate inflammation, metabolism, and cancer by controlling key signaling pathways [3]. In response to this intricate landscape, the goal of this Special Issue is to consolidate recent studies and discoveries that shed light on the molecular mechanisms of cell signaling mediated by Tribbles pseudokinases in cancer, aiming to conceptualize the available evidence. This Special Issue, titled “Pseudokinases, Tribbles Proteins, and Cancer,” encompasses six original articles, seven review articles, and one commentary, each advancing knowledge in this research field., This work was supported by the Spanish Ministry of Science, Innovation and Universities through Grant RTI2018-094629-B-I00 to WL. Tribbles-related work in GV laboratory was supported by the Instituto de Salud Carlos III (ISCIII) and confounded by the European Regional Development Fund (ERDF), “A way to make Europe”, grant number PI18/00442 integrated into the State Plan for R & D + I 2017-2020 and grant number PI21/00343 integrated into the State Plan for R & D + I 2021-2023, by the European Commission through the Horizon 2020 European Training Networks program, grant number H2020-MSCA-ITN-308 2016 721532; and by the Breast Cancer Now (formerly Breast Cancer Campaign) foundation, grant number 2012NovSP033., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Integrative analysis of transcriptomics and clinical data uncovers the tumor- suppressive activity of MITF in prostate cancer

  • Valcarcel Jimenez, Lorea
  • Macchia, Alice
  • Martín Martín, Natalia
  • Cortazar, Ana Rosa
  • Schaub Clerigué, Ariane
  • Pujana Vaquerizo, Mikel
  • Fernández Ruiz, Sonia
  • Lacasa-Viscasillas, Isabel
  • Santos Martin, Aida
  • Loizaga Iriarte, Ana
  • Unda Urzaiz, Miguel
  • Hermanova, Ivana
  • Astobiza, Ianire
  • Graupera i Garcia-Milà, Mariona
  • Starkova, Julia
  • Sutherland, James David
  • Barrio, Rosa
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Torrano, Verónica
The dysregulation of gene expression is an enabling hallmark of cancer. Computational analysis of transcriptomics data from human cancer specimens, complemented with exhaustive clinical annotation, provides an opportunity to identify core regulators of the tumorigenic process. Here we exploit well-annotated clinical datasets of prostate cancer for the discovery of transcriptional regulators relevant to prostate cancer. Following this rationale, we identify Microphthalmia-associated transcription factor (MITF) as a prostate tumor suppressor among a subset of transcription factors. Importantly, we further interrogate transcriptomics and clinical data to refine MITF perturbation-based empirical assays and unveil Crystallin Alpha B (CRYAB) as an unprecedented direct target of the transcription factor that is, at least in part, responsible for its tumor-suppressive activity in prostate cancer. This evidence was supported by the enhanced prognostic potential of a signature based on the concomitant alteration of MITF and CRYAB in prostate cancer patients. In sum, our study provides proof-of-concept evidence of the potential of the bioinformatics screen of publicly available cancer patient databases as discovery platforms, and demonstrates that the MITF-CRYAB axis controls prostate cancer biology.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle

  • Cordani, Marco
  • Strippoli, Raffaele
  • Trionfetti, Flavia
  • Barzegar Behrooz, Amir
  • Rumio, Cristiano
  • Velasco, Guillermo
  • Ghavami, Saeid
  • Marcucci, Fabrizio
Inhibitory immune checkpoint (ICP) molecules are pivotal in inhibiting innate and acquired antitumor immune responses, a mechanism frequently exploited by cancer cells to evade host immunity. These evasion strategies contribute to the complexity of cancer progression and therapeutic resistance. For this reason, ICP molecules have become targets for antitumor drugs, particularly monoclonal antibodies, collectively referred to as immune checkpoint inhibitors (ICI), that counteract such cancer-associated immune suppression and restore antitumor immune responses. Over the last decade, however, it has become clear that tumor cell-associated ICPs can also induce tumor cell-intrinsic effects, in particular epithelial-mesenchymal transition (EMT) and macroautophagy (hereafter autophagy). Both of these processes have profound implications for cancer metastasis and drug responsiveness. This article reviews the positive or negative cross-talk that tumor cell-associated ICPs undergo with autophagy and EMT. We discuss that tumor cell-associated ICPs are upregulated in response to the same stimuli that induce EMT. Moreover, ICPs themselves, when overexpressed, become an EMT-inducing stimulus. As regards the cross-talk with autophagy, ICPs have been shown to either stimulate or inhibit autophagy, while autophagy itself can either up- or downregulate the expression of ICPs. This dynamic equilibrium also extends to the autophagy-apoptosis axis, further emphasizing the complexities of cellular responses. Eventually, we delve into the intricate balance between autophagy and apoptosis, elucidating its role in the broader interplay of cellular dynamics influenced by ICPs. In the final part of this article, we speculate about the driving forces underlying the contradictory outcomes of the reciprocal, inhibitory, or stimulatory effects between ICPs, EMT, and autophagy. A conclusive identification of these driving forces may allow to achieve improved antitumor effects when using combinations of ICIs and compounds acting on EMT and/or autophagy. Prospectively, this may translate into increased and/or broadened therapeutic efficacy compared to what is currently achieved with ICI-based clinical protocols.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.